NCT02211014View on ClinicalTrials.gov

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

PHASE1CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

April 26, 2019

Study Completion Date

April 26, 2019

Conditions

Multiple Myeloma (MM)

Interventions

DRUG

acalabrutinib

Trial Locations (3)

Unknown

Baltimore

United Kingdom, Leicester

Guys and St Thomas' Hospital NHS Foundation Trust, London

Sponsors

Lead Sponsor

Acerta Pharma BV

Collaborators (1)

Acerta Pharma, LLC

All Listed Sponsors

collaborator

Acerta Pharma, LLC

OTHER

lead

Acerta Pharma BV

INDUSTRY